Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel
- Recruiting
- Bnai Zion Medical Center
-
Contact:
- Elad Schiff
- Phone Number: 97248359281
- Email: eschiff@email.arizona.edu
-
Principal Investigator:
- Elad Schiff
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic carriers of hepatitis C who start a course of interferon alpha treatment, and are treated in the liver clinic of Bnai Zion hospital.
Exclusion Criteria:
- Disagreement to participation in trial.
- Diagnosed and active mental illness.
- Encephalopathic patients.
- Patients with limited ability to understand the questionnaires or the informed consent process.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The effect of omega three fatty acids would be estimated through two questionnaires which filled by the patients monthly
|
|
with the BDI questionnaire which estimates the level of depression of the patient and
|
|
the SF36 questionnaire which provides information about the overall influence of a disease upon a patient's daily life and mental status.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
CRP
|
|
Secondary outcome measures include monthly results of biochemical and hematologic blood tests, including levels of:
|
|
albumin
|
|
bilirubin
|
|
ALT
|
|
hemoglobin
|
|
WBC
|
|
platelets
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elad Schiff, MD, affiliated with Bnai Zion MC
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Depression
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
Other Study ID Numbers
Other Study ID Numbers
- Schiff1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.